At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 803 enrolled
Drug / intervention
Pirtobrutinib +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1/2 Study of Oral LOXO-305 in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) or Non-Hodgkin Lymphoma (NHL)
In Brief
A Phase 2 clinical trial evaluating Pirtobrutinib, Venetoclax, and 1 other intervention for Chronic Lymphocytic Leukemia and 5 related conditions. Completed, enrolled 803 participants across 56 sites in 10 countries.
Detailed Summary
This is an open-label, multi-center Phase 1/2 study of oral LOXO-305 (pirtobrutinib) in patients with CLL/SLL and NHL who have failed or are intolerant to standard of care.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Lymphocytic Leukemia, Waldenstrom Macroglobulinemia, Mantle Cell Lymphoma, Marginal Zone Lymphoma, B-cell Lymphoma, Small Lymphocytic Lymphoma
CountriesAustralia, France, Italy, Japan, Poland, South Korea, Sweden, Switzerland, United Kingdom, United States
CollaboratorsEli Lilly and Company
Timeline
Phase 2CompletedFinished
20192020202120222023202420252026
First PostedNov 2018
Enrollment StartMar 2019
Primary CompletionJan 2025
Study CompletionDec 2025
TodayJul 2026
First PostedNov 14, 2018
Enrollment StartMar 15, 2019
Primary CompletionJan 27, 2025
Study CompletionDec 23, 2025
TodayJul 2, 2026
Enrollment to primary: 5.9 yearsPosted 7.6 years ago
Interventions
Pirtobrutinibdrug
Oral
Venetoclaxdrug
Oral
Rituximabdrug
IV